AC
INDV icon

Aristides Capital’s Indivior Pharmaceuticals INDV Stock Holding History

Aristides Capital’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,540
Closed -$278K – 307
2025
Q3 		$278K Buy
+11,540
New +$241K 0.04% 182

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Aristides Capital's INDV Position: Q4 2025 in Review

Aristides Capital sold out of Indivior Pharmaceuticals (INDV) in Q4 2025, closing a stake of 11,540 shares — an estimated $278K sold.

Aristides Capital first reported a position in INDV in Q3 2025 and held it in 1 quarter. The position peaked at $278K in Q3 2025. 259 funds tracked by Wall St. Rank hold INDV as of Q4 2025.

  • Aristides Capital reported no remaining Indivior Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Aristides Capital sold 11,540 Indivior Pharmaceuticals shares in Q4 2025, an estimated $278K.
  • Aristides Capital first reported a position in Indivior Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Aristides Capital's Indivior Pharmaceuticals position peaked at $278K in Q3 2025.
  • 259 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q4 2025.

Based on Aristides Capital's 13F filing for Q4 2025, filed 12 Feb 2026.